Home > Neurology > EAN 2020 > Multiple Sclerosis > Switching from natalizumab to moderate- versus high-efficacy DMT

Switching from natalizumab to moderate- versus high-efficacy DMT

Presented By
Dr Carrie M. Hersh, Cleveland Clinic Lerner College of Medicine, OH, USA
Conference
EAN 2020
Multiple sclerosis (MS) patients switching from natalizumab to another high-efficacy therapy had more favourable inflammatory and disability outcomes after 24 months than patients who deescalated to a moderate-efficacy disease-modifying therapy (DMT), which yielded greater disability progression [1]. The effect of such a treatment change was assessed after 24 months of follow-up. The 556 participants discontinued natalizumab treatment between 2005 and 2018 for various reasons, including progressive multifocal leukoencephalopathy risk (54.9%), breakthrough disease (15.3%), and adverse effects (17.3%). Of those participants, 270 (48.6%) switched to moderate-efficacy DMT (dimethyl fumarate, n=130; fingolimod, n=140), while 130 (23.4%) switched to high-efficacy therapy (ocrelizumab, n=106; rituximab, n=17; alemtuzumab, n=7). At 24 months, there were no differences in annualised relapse rate (OR 1.44; 95% CI 0.69-1.59; P=0.334). However, a significantly ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on